Buscar resultados de ensayos clínicos
Adenoma, Islet Cell - 110 Studies Found
Estado | Estudiar |
Not yet recruiting |
Nombre del estudio: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib Condición: Pancreatic Neuroendocrine Tumour Metastatic Fecha: 2016-03-16 Intervenciones: Drug: Sunitinib Sunitinib 37.5 mg/day |
Not yet recruiting |
Nombre del estudio: Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival Condición: Pancreatic Neuroendocrine Tumor Fecha: 2015-11-30 Intervenciones: Procedure: pancreatectomy Remove the pancreatic neuroendocrine tumor by surgery |
Recruiting |
Nombre del estudio: Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Condición: Neuroendocrine Tumors Fecha: 2015-10-26 Intervenciones:
|
Recruiting |
Nombre del estudio: Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Condición:
Fecha: 2015-10-12 Intervenciones: Drug: Ibrutinib Ibrutinib will be administered orally once daily and each cycle will be defined as 4 wee |
Recruiting |
Nombre del estudio: Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors Condición: Neuroendocrine Tumors Fecha: 2015-06-16 Intervenciones:
|
Completed |
Nombre del estudio: An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms Condición: Pancreatic Endocrine Neoplasms Fecha: 2015-03-23 |
Recruiting |
Nombre del estudio: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus Condición: Pancreatic Neuroendocrine Tumour Metastatic Fecha: 2014-06-17 Intervenciones: Drug: Everolimus 10 mg daily everolimus is a recently approved mTOR inhibitor in advanced progressing we |
Recruiting |
Nombre del estudio: A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Condición: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours Fecha: 2014-09-23 Intervenciones:
|
Recruiting |
Nombre del estudio: The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors Condición: Pancreatic Neuroendocrine Tumors Fecha: 2014-10-15 Intervenciones: Drug: sunitinib subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg on |
Recruiting |
Nombre del estudio: Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (pNET): A Study Of Morbidity And Mortality At 2 Years Condición: Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive Fecha: 2014-09-02 Intervenciones:
|